Tesaro
Clinical trials sponsored by Tesaro, explained in plain language.
Now part of
GSK plc
GSK
NYSE
Oncology biotech acquired by GSK, known for cancer drug Zejula.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immunotherapy plus chemo shows promise in advanced uterine cancer trial Results expected Nov 2026 (estimated)
- New antibody TSR-022 takes on advanced cancers in first human trial Results expected Mar 2027 (estimated)